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Synthesis and preclinical validation
of novel P2Y1 receptor ligands as a
potent anti-prostate cancer agent
Hien Thi Thu Le1, Tatu Rimpilainen2, Saravanan Konda Mani 3, Akshaya Murugesan1,4,
Olli Yli-Harja5,6, Nuno R. Candeias2 & Meenakshisundaram Kandhavelu 1*
Purinergic receptor is a potential drug target for neuropathic pain, Alzheimer disease, and prostate
cancer. Focusing on the structure-based ligand discovery, docking analysis on the crystal structure of
P2Y1 receptor (P2Y1R) with 923 derivatives of 1-indolinoalkyl 2-phenolic compound is performed to
understand the molecular insights of the receptor. The structural model identified the top novel ligands,
426 (compound 1) and 636 (compound 2) having highest binding affinity with the docking score of
−7.38 and −6.92. We have reported the interaction efficacy and the dynamics of P2Y1R protein with
the ligands. The best hits synthesized were experimentally optimized as a potent P2Y1 agonists. These
ligands exhibits anti-proliferative effect against the PC-3 and DU-145 cells (IC50 = 15 µM – 33 µM) with
significant increase in the calcium level in dose- and time-dependent manner. Moreover, the activation
of P2Y1R induced the apoptosis via Capase3/7 and ROS signaling pathway. Thus it is evidenced that the
newly synthesized ligands, as a P2Y1R agonists could potentially act as a therapeutic drug for treating
prostate cancer.
Prostate cancer (PCa) is the most common cause of cancer deaths in men1. It has been characterized as a complex disease induced by the alteration in intrinsic and extrinsic cellular processes2. G-protein coupled receptors
(GPCRs), the largest family of cell surface receptor plays a key role in metastatic cancer and hence considered
as the promising targets for cancer treatment3,4. However, the substantial role of GPCRs in cancer progression
and treatment remains questionable. Purinergic receptors (P2YRs), another member of GPCR family, found
to be over-expressed in some types of cancer cells and tissues5. Based on the differences in gene sequence, protein structure, and functions, the P2YR family constitutes 8 homo-receptor subtypes, such as P2Y1, P2Y2, P2Y4,
P2Y6, P2Y11, P2Y12, P2Y13, and P2Y146. Of late, it has been identified that P2Y1 expression is higher in PC-37–9
and DU-145 cells9,10 both in normal and stimulation condition than in non-cancerous cells. Therefore, P2Y1R
is considered as a noteworthy tumor cell marker and anticipated to be used as a target for inhibiting the PCa cell
proliferation.
The stimulations of P2Y1R induce corresponding signal transduction pathways that varied for different cell
types11. The selected P2Y1R-targeted agonist, MRS 2365 increases lactate dehydrogenase and intracellular calcium (Ca2+) levels, in turn induces apoptosis and inhibits the PC-3 cells proliferation8. Furthermore, 2-MeSADP,
a non-selective P2Y1 agonist, stimulates intracellular Ca2+, cell death and reduces cell aggression in 1321N1 astrocytoma cells transfected with the human P2Y1R12,13. Still, in HUVEC cells, a P2Y1R antagonist MRS2179 leads to
the formation of phosphatydilinositol, and phosphorylates the mitogen-activated protein kinases (MAPK)14,15.
The activation of MAPK signaling possibly contributes to the re-endothelialization after vascular injury14,15.
Other potential therapeutic applications for P2Y1R ligands includes, agonist as antidiabetic agents or antagonists as antithrombotic agents in vitro and in vivo models16–18. Although there is expression of P2Y1R in the
human prostate, its role in the growth of PCa is yet to be characterized. In the present study, PC-3 and DU-145
PCa cells19,20, were used to investigate the effect of P2Y1R and novel agonists in cell death and proliferation. Many
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Figure 1. Hit identification based on docking score. (A) Library of 1-indolinoalkyl 2-phenols for P2Y1R
docking screen. (B) Glide docking score (kcal/mol) of 923 compounds against P2Y1R. Two ligand-like
compounds 1 and 2 ranks top with high docking scores.

scaffolds such as 1,4-substituted triazoles, pyrimidines or pyrazoles are known for their antitumor activities21–23.
Similarly, phenolic Mannich bases were recognized to possess anticancer and cytotoxic activity24. Derivatives
of aminomethylated naphthols and 8-hydroxyquinoline induces apoptosis on activation of caspase-dependent
pathways24,25.
Our earlier reports have also demonstrated the ability of 1-indolinoalkyl 2-phenols to inhibit cancer cells
growth26. Since phenolic compounds have profound role in inhibiting the cancer cell proliferation, a large variety
of substituents of 1-indolinoalkyl 2-phenols is considered in the initial library for the docking studies. We synthesized a group of 1-indolinoalkyl 2-phenolic derivatives using 3-component Petasis borono-Mannich reaction
(i.e., salicylaldehydes, indolines and boronic acids) and many potential hits are experimentally verified. Based on
the probability of targeted P2Y1R signaling activation to inhibit PCa cell growth, a library of over 900 structures
was built with single variation in the substituents from the different components along with their combinations.
The best docking poses in the ligands interaction with P2Y1R was further analyzed. The detailed interaction of the
three-dimensional structure of P2Y1R with the selective antagonist MRS2179 was performed for scrutinizing the
newly synthesized ligands. The competence of new P2Y1 ligand identified via molecular modeling, docking, and
calcium kinetics is analyzed. The activation of P2Y1R down-stream signaling pathway and their effect in PCa is
also explored through apoptosis, ROS and Caspase 3/7 assays. Our findings suggested that the identified ligands
might potentially help in the treatment of the prostate cancer.

Results and Discussion

Novel ligands of P2Y1R. The three – dimensional (3D) coordinates of P2Y1R was retrieved from Protein
Data Bank with the code 4XNW (Resolution: 2.7 Å) comprising of 427 amino acid residues. The P2Y1 protein
model shares a canonical seven transmembrane helices each flanked by the topological domain like other known
GPCR structures27,28. To study the binding mode of P2Y1R, initially we performed the docking studies with the
known antagonist MRS2500 (co-crystallized)29, and an agonist MRS2365 (glide score −8.80 Kcal/mol) using
Schrodinger. Over 900 compounds were designed using Java Molecular Editor (JME) and translated to structure
data file which is compiled in the repository (Table S2 of SI) (Fig. 1A). P2Y1R model was docked with 923 compounds (Fig. 1B and Table S2 of SI). The docked results were analyzed based on the presence of hydrogen bonds,
salt bridges, halogen bonds, aromatic bonds, π-cation and π-π interactions. All the conformers were scrutinized
based on the binding mode and the stability of the protein-ligand complex. The library comprising 923 compounds was screened based on the docking score that are −7.0 and above (Fig. 1B and Table S2 of SI). The best
two ligand like compounds 1 and 2 with the highest docking score, that satisfies Lipinski’s rule were selected. The
high glide score indicated a high binding affinity towards the P2Y1R.
2D ligand interaction diagram showed the similar number of interaction of ligands with amino acid residues
in the P2Y1R, 1 with 16 interactions (Fig. 2A) and 2 with 19 interactions (Fig. 2B). Six hydrophobic interactions were found between 1 and P2Y1R while seven interactions between 2 and the receptor. Both ligands form
interaction with cysteine, tyrosine and sulfur containing amino acid residues of the P2Y1R. The Hydrophobic
contact between the protein and ligands are the key property for the protein folding and stability30. The charged
residue interactions were also observed between ligands and P2Y1R molecule at Arg287. Cation-pi stabilizing
Scientific Reports |

(2019) 9:18938 | https://doi.org/10.1038/s41598-019-55194-8

2

www.nature.com/scientificreports/

www.nature.com/scientificreports

Figure 2. The ligand binding residues of the receptor is shown as the surface model and the ligand is shown
in black colored ball and stick model (A) compound 1 and P2Y1 (B) compound 2 and P2Y1. The non-ligand
interacting regions of receptor is shown as ribbon model. (C) Two-dimensional ligand interaction diagram
of compound 1 and (D) compound 2. The color coding and interactions are described in the ligand key. (E)
Synthesis scheme of 1-indolinoalkyl 2-phenols 1 and 2.

electrostatic interactions were found in similar number in both the ligands (Fig. 2C,D). There are a few interactions found to be conserved on both P2Y1R-ligand 1 and 2 complexes at the amino acid residues such as Arg287,
Arg310, Arg195 (Charged38), Tyr303, Cys42, Cys202 (Hydrophobic), and Leu44. The presence of cysteine residues at the interface is also essential for maintaining the precise pocket formation that allows the receptor to bind
with the ligands30. These observations suggest that both ligands have the potentiality to bind with P2Y1R.
The identified promising hits were organized through the abovementioned Petasis borono-Mannich reaction
(Fig. 2E). Indoline-4-carbonitrile was prepared with 68% yield on reducing the corresponding indole with triethylsilane in TFA31. Both 1-indolinoalkyl 2-phenols was obtained in good yields upon reaction at 50 °C, while
preparation of 2 requires longer reaction time (20 h vs 70 min for 1) due to the lower reactivity of the boronic acid
partner.

Novel ligand-P2Y1R interaction and signaling activation affects intracellular calcium.

The
activation of phospholipase C (PLC) is the common signal transduction pathway triggered by the P2Y1R-Gq32.
Phosphatatidylinositol-4,5-bisphosphatase is hydrolyzed by the PLC activation, which increases the cytosolic
Ca2+ mobilization through the generated IP3 and diacylglycerol33. To elucidate the agonistic activity of these
two compounds, we analyzed the changes in the downstream effector, Ca2+ in PCa cells34. As shown in Fig. 3,
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Figure 3. Measurement of intracellular calcium with Fura 2-AM on activation of P2Y1R by compound 1 and
2. The fluorescence was measured using MagelanTM microplate plate reader at every 5 min. The ratiometric
Ca2+ fold change was analyzed based on the emitted fluorescence intensities of the samples. PC-3 cells were
treated with (A) compound 1, (B) compound 2 and DU-145 cells with (C) compound 1 and (D) compound 2.
(E) P2Y1R silencing by siRNA and and its effect on Ca2+ signaling activation by compound 1, 2 and MRS2365
in PC-3 cells (F) same condition as “E” in DU-145 cells. The experiments were repeated 3 independent times,
*p < 0.05 by one-way ANOVA.

intracellular Ca2+ concentration increases in PC-3 (Fig. 3A,B) and DU-145 (Fig. 3C,D) cells over the concentration of compound 1 and 2 in a time dependent manner. As evident from Fig. 3A,C, compound 1 at 100 µM
concentration increased the Ca2+ level in PC-3 and DU-145 cells which is 5 fold higher than the untreated condition after 60 min. Similarly, compound 2 at 25 µM also increased the Ca2+ by 3 fold higher than the untreated
condition after 60 min. siRNA assay was also performed to confirm the P2Y1R targeted binding of the compound
1 and 2. In the absence of P2Y1 siRNA, there was 1.3 fold higher level of Ca2+ upon the activation of P2Y1R signal
by MRS2365, compound 1 and 2, whereas the presence of P2Y1 siRNA showed 0.2 fold decrease in the level of
Ca2+ in PC-3 cells (Fig. 3E) and DU- 145 cells (Fig. 3F). These results shows the P2Y1R specific interaction of the
novel ligands that can act as an agonist which is congruent with the virtual screening results.

Growth inhibitory effects of compound 1 and 2 on PC-3 and DU-145 cells.

P2Y1R has been used
as a biomarker for the therapeutic treatments of PCa cells35,36 and its agonists acting as an cell death inducer9,12. In
the present study, compound 1 and 2 were chosen as an ideal ligand based on its potentiality to bind and interact
with the P2Y1R. Further to explore the cytotoxicity effect of these two ligands against the growth of PCa cells,
MTT assay was performed. PC-3 and DU-145 cells were treated with varying concentrations of compound 1 and
2. As given in the Fig. 4A, the compounds decreased the cell viability when relatively compared with the untreated
control group. Dose-dependent experiment on PC-3 cells revealed the IC50 values as 15.98 µM for compound 1
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Figure 4. Effect of compound 1 and 2 on the cell viability. (A) PC-3 cells and (B) DU-145 cells were treated
with the varying concentrations of compound 1 and 2. IC50 of the untreated cells along with the respective
compounds were determined by Prism 7.0. (C) PC3 and DU-145 cells and (D) HEK293 and MEF cells were
treated with 100 µM of compound 1 and 2, MRS2365 for 48 h with DMSO as negative control. (E) PC-3 and
(F) DU-145 cells were incubated with the IC50 concentration of compound 1 and 2 and 50 µM Na3VO4 for 24 h,
48 h, and 72 h. The experiment was performed with replicates of biological and technical repeats. Statistical
significance was considered at *p < 0.05.

and 33.57 µM for compound 2. Apparently, IC50 values for DU-145 cells was found to be 15.64 µM for compound
1 and 25.64 µM for compound 2 (Fig. 4B). Based on the IC50 values, compound 1 exerted a better cytotoxic effect
on PCa cells than compound 2. Notably, compound 1 and 2 induced ~96% of cell death in PCa cells whereas
MRS2365, the positive control of P2Y1R agonist, induced about 38% of cell death (Fig. 4C). In contrast, HEK293
and MEF, non-cancerous cells, were significantly less sensitive when treated with compound 1, 2, and MRS365
than the PCa cells (Fig. 4D). The cell death of non-cancerous cells was observed to be less than 20% with 100 μM
concentration of compound 1 and 2 treatment. These observation concluded that the compound 1 and 2 have
cytotoxic effect specific for PCa cells.
To detect the effect of the compounds, the PC-3 and DU-145 cells were treated at different time points with
IC50 concentration of 1 and 2. Figure 4E,F have shown that the cell proliferation in the treated cells were significantly lower than the control group over the time. The effect of compound 1 and 2 on PC-3 reduced the cell
proliferation to about 89%, 67%, and 42% and 90%, 69%, 40% respectively at 24 h, 48 h, and 72 h. Similarly, the
impact of Na3VO4 on PC-3 cells have shown the reduced proliferation of about 92%, 81%, and 45% at 24 h, 48 h,
and 72 h, respectively. The inhibition of cell proliferation of the compound 1 and 2 was higher than the positive
control Na3VO4 at 48 h (Fig. 4E). In contrast, DU-145 cells, the cell growth was reduced from ~85% to ~60%
progressively from 24 h to 48 h on treatment with compound 1, 2 and Na3VO4 (Fig. 4F). However, at 72 h, the
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Figure 5. Induction of apoptosis by compound 1 and 2 on PCa cells. (A) Representative images of PC-3 cells
stained with Annexin-V/PI in untreated, compound 1, 2, and Na3VO4 treated condition. (B) percentage of
apoptotic and necrotic cell death in the corresponding condition as in A. (C) The representative images of DU145 cells stained with Annexin-V/PI (D) the percentage of apoptosis and necrosis in DU-145 cells. Results are
represented as mean of three independent experiments, mean ± S.D. *P < 0.05, versus control, n = 3.
proliferation was inhibited to 43% on treatment with compound 1 and 2, which was higher than Na3VO4 treatment. These findings supports the hypothesis that compound 1 and 2 could inhibit the cancer cell proliferation
on increasing the treatment time.

Effects of compound 1 and 2 on PCa apoptosis.

Apoptosis is a common response to cell stress during
the process of cell death37 which can happen through the increase of intracellular Ca2+, ROS and the activation of
caspase38. We sought to determine the efficacy of the novel agonists 1 and 2 on PCa cell lines, Annexin V-affinity
assay was performed. After 48 h of treatment, the fluorescent microscope images of PC-3 (Fig. 5A) and DU-145
cells (Fig. 5B) exposed the presence of apoptotic and necrotic cells. PC-3 cells on treatment with compound 1 and
2 caused apoptosis of 23.2% and 29.6% whereas the positive control Na3VO4 caused 25.6% apoptosis (Fig. 5C).
DU-145 cells after 48 h treatment with compound 1, 2 and Na3VO4 is marked with 20% increase in apoptotic cell
fraction when compared to the untreated cells (Fig. 5D). Taken together, we conclude that the activation of P2Y1R
by the compound 1 and 2 increases the cell death through apoptosis.

Production of ROS by compound 1 and 2 in PCa cells. ROS production exists under normal and
abnormal physiological conditions of the cell39. The production of ROS affects several signaling pathways such
as cell survival, phosphatase and kinase activities, and muscle plasticity40. ROS promotes many events of tumor
progression like cell proliferation, metastasis, and angiogenesis41. ROS is also capable of inducing cell cycle arrest
and cell death in cancer treatment42. In order to explore the effect of P2Y1R activation on prostate cancer via ROS,
PC-3 and DU-145 cells were incubated with compound 1, 2, and H2O2. As shown in Fig. 6, the production of
ROS increased in the presence of H2O2, compound 1 and 2 in PC-3 and DU-145 cells (Fig. 6A). We noticed an
increase in the fold change of ROS to 1.41 and 1.22 in the compound 1 and 2 treated PC-3 cells respectively, when
compared to the untreated condition. The positive control H2O2 expressed 2.1 fold change in ROS level which is
greater than the compound 1 and 2 treatment. Likewise, ROS level in DU-145 cells also increased to 1.36 and 1.01
fold change on treatment with compound 1 and 2 whereas H2O2 showed 1.78 ROS fold change. The difference in
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Figure 6. Production of ROS and activation of Caspase3/7 by compound 1 and 2 in PCa cells. (A) The fold
change in ROS in PC-3 and DU-145 cells treated with compound 1, 2 and H2O2. H2DCFDA labelled cells was
used to measure the ROS production and its fluorescence signal was recorded using 96 well plate reader. The
fold change of ROS was calculated using fluorescence intensities of the untreated control. (B) The fold change
in Caspase 3/7 in PC-3 and DU-145 cells treated with compound 1, 2, and Na3VO4. Biological and the technical
replicates were maintained to assess the significance of the results, with mean ± S.D. *P < 0.05, versus control,
n = 3.

the fold change was proven to be statistically significant by ANOVA test with the P-value < 0.05 (Table S1 of SI).
These results indicates that the agonists 1 and 2 enhanced the production of ROS in both PCa cells.

Activation of Caspase 3/7 by compound 1 and 2 on PCa.

Apoptosis is induced through the activation
of intracellular caspases and lead to the modification of protein substrate within the nucleus and cytoplasm43.
Currently more than 14 caspases were cloned and partially their functions were determinuteed to be in programmed cell death44. Among them, caspases 3 and 7 have been identified as an executioner caspases that directly
lead to the intrinsic/extrinsic pathways in apoptosis process45,46. Since the caspase plays an essential role in cell
death, the anti-cancer effect of agonist 1 and 2 were explored by determinuteing the changes in the caspase 3/7
activity. As described in the Caspase-Glo 3/7 assay, PC-3 and DU-145 cells were treated with compounds 1, 2,
and Na3VO4. Interestingly, PC-3 cells treated with compound 1 exhibited an increase of caspase 3/7, showing 1.22
fold induction when compared to the untreated cells (Fig. 6B). Besides, compound 2 and positive control exhibited 0.8 and 1.26 fold induction, respectively. However, Caspase 3/7 activity increased similarly around 1.15-fold
change in DU-145 cells on treatment with compound 1 and 2 than the untreated condition. The difference in the
fold change of treated and untreated conditions were statistically significant as per ANOVA test (P-value < 0.05;
Table S1 of SI). Collectively, the results demonstrated that the novel agonist 1 and 2 could induce apoptosis
through Caspase 3/7 dependent signaling pathway.

®

Conclusion

P2Y1R, a purinergic Gq protein, has been reported as the pharmacological target for the therapeutic treatment
of PCa20,47,48. In the present research, molecular docking experiments was performed to investigate the interaction of a library of 923 1-indolinoalkyl 2-phenolic derivatives with P2Y1R protein. Docking analysis revealed
that the compound 1 and 2 as the novel ligands. Furthermore, interactions of P2Y1R between these two ligands
demonstrated the crucial aminuteo acid interactions responsible for the folding and stability. The synthesized
1-indolinoalkyl 2-phenolic derivatives 1 and 2 were purified and used for the activation of P2Y1R, resulted in the
increase of intracellular Ca2+ in PCa cell. The compound 1 and 2 induced Ca2+ level in a dose/time-dependent
manner suggesting that these compounds are agonists for P2Y1R. In addition, the activation of P2Y1R induced
the cell death with IC50 concentration of 15–33 µM. The compound 1 and 2 promoted apoptosis and necrosis
which increased ROS production and caspase 3/7 signaling. These results demonstrated that the findings are
consistent with the earlier reports on the functional effect of P2Y1R activation in PCa cells8,49. We suggest that
P2Y1R might be an attractive target for the treatment of prostate cancer. Thus it is concluded that the synthesized
1-indolinoalkyl 2-phenolic derivatives 1 and 2 could provide the new opportunity to develop P2Y1-signaling
mediated drugs for the treatment of PCa.

Materials and Methods

Structure model. Structure of the P2Y1R was retrieved from PDB with the identification code 4XNW49. The

crystal structure of the human P2Y1R in complexed with the nucleotide antagonist MRS2500 at 2.7 Å resolution
is used as a reference compound. Protein Preparation Wizard in Maestro50 is used for the preparation of the
3D structure of the protein. Protein structure was stabilized by adding and optimizing the hydrogen atoms and
bonds, removing atomic clashes, adding formal charges to the hetero groups and then optimizing at neutral pH.
Finally, the structure was minuteimized with optimized potential for liquid simulations force field (OPLS-2005).
The ligand binding site observed in the crystal structure is used as the control binding site whereas, docked complex with the known agonist, MRS2365 is used as the positive control. This is used to perform the further docking
of 923 conformers.

Ligand library.

The two-dimensional structures of 923 aminuteobenzylated phenols were generated using
RD Kit library for Python and exported to Structure Data File (SDF). The ligand molecules were subjected to
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LigPrep module of Schrödinger suite51. This module is used to generate the possible low energy stereoisomers
with standard physical conditions. The prepared 923 ligands were subjected to high throughput virtual screening
using the GLIDE (Grid based Ligand and Docking with Energetics) module of Schrödinger suite52.

Docking screening.

Receptor grid box for the 923 compounds were generated using the ligand binding
site of the crystal structure (P2Y1R complexed with MRS2500). Ligands were docked to the protein using Glide
software. Docking was performed in a “Standard Precision” (SP) mode and then by “Extra precision” mode (XP).
The docked conformers were evaluated using Glide (G) Score53.

Design and synthesis of P2Y1 ligands with general remarks. The reactions were performed using the

reagents from Sigma-Aldrich or TCI, and the experiment was performed under argon atmosphere. Thin-layer
chromatography was done on pre-coated (Merck TLC silica gel 60 F254) aluminuteium plates, developed using
cerium molybdate solution and visualized under UV light. Flash column chromatography was done on silica
gel 60 (Merck, 0.040–0.063 mm). NMR spectra were recorded (Jeol ECZR 500) using CDCl3 as solvent and calibration was done using tetramethylsilane as internal standard. Chemical shifts in ppm (δ) are specified to the
CDCl3 residual peak (δ 7.26) or TMS peak (δ 0.00) for 1H NMR, to CDCl3 (δ 77.16) for 13C NMR. The peak
splitting patterns were designated as; s = singlet, d = doublet, t = triplet, m = multiplet. Coupling constants, J, is
represented in Hertz (Hz). High-resolution mass spectra was recorded on the Waters ESI-TOF MS spectrometer.
Elemental analysis to detect C, N and H was determinuteed on Elementar vario EL III. Tested compounds shows
purity > 95% upon elemental analysis. Indoline-4-carbonitrile was prepared as the earlier method for reducing
the corresponding indole with triethylsilane31 with the same spectral characterization54 (Fig. S1 of SI).

1-(2-Hydroxy-5-nitrophenyl)(4-hydroxyphenyl)methyl)indoline-4-carbonitrile (1).

Indoline4-carbonitrile (71 mg, 0.5 mmol) was added to 2-hydroxy-5-nitrobenzaldehyde (84 mg, 0.5 mmol, 1 equiv) and
(4-hydroxyphenyl) boronic acid (69 mg, 0.5 mmol, 1 equiv) in 5.0 mL DCE and 0.5 mL EtOH at 50 °C. The reaction was stirred for 70 minuteutes and the solvents were evaporated under reduced pressure. The gradient column chromatography was to purify the residue (DCM to DCM/EtOAc 85:15) to give compound 1 (152.7 mg,
0.39 mmol, 79% yield) as a light yellow solid. 1H NMR (500 MHz, CDCl3) δ 10.42 (br. s, 1 H), 8.12 (dd, J = 9.2,
2.9 Hz, 1 H), 7.98 (d, J = 2.9 Hz, 1 H), 7.24 (d, J = 8.6 Hz, 2 H), 7.12–7.06 (m, 2 H), 6.97 (d, J = 9.2 Hz, 1 H), 6.84
(d, J = 8.6 Hz, 2 H), 6.60 (d, J = 8.0 Hz, 1 H), 5.55 (br. s, 1 H), 5.38 (s, 1 H), 3.33 (td, J = 8.7, 3.8 Hz, 1 H), 3.25–
3.07 (m, 3 H). 13C NMR (126 MHz, CDCl3) δ 161.9, 156.4, 151.1, 141.2, 136.9, 130.3, 129.3, 128.8, 126.6, 125.5,
125.0, 124.5, 117.8, 117.3, 116.3, 115.6, 109.2, 68.3, 52.9, 28.1. Elemental analysis: Calcd for C22H17N3O4: C, 68.21;
H, 4.42; N, 10.85. Found: C, 65.03; H, 4.47; N, 9.81. HRMS (ESI/TOF): m/z calcd for C22H16N3O4− [M − H]−,
386.1146; found 386.1129 (Fig. S2 and S3 of SI).

Methyl 4-((4-cyanoindolin-1-yl)(2,5-dihydroxyphenyl)methyl)benzoate (2). Indoline4-carbonitrile (71 mg, 0.5 mmol) was added to a solution of 2,5-dihydroxybenzaldehyde (69 mg, 0.5 mmol, 1
equiv) and (4-(methoxycarbonyl)phenyl)boronic acid (90 mg, 0.5 mmol, 1 equiv) in 5.0 mL DCE at 50 °C. The
reaction was agitated continuously for 20 h and the solvent were evaporated under reduced pressure. The residue
was purified (gradient column chromatography, hexane/iPrOH 85:15 to hexane/iPrOH 80:20) to produce compound 2 (165.3 mg, 0.41 mmol, 83% yield) as an off-white solid. 1H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 8.0 Hz,
2 H), 7.40 (d, J = 8.6 Hz, 2 H), 7.31 (br. s, 1 H), 6.95 (t, J = 7.7 Hz, 1 H), 6.90 (d, J = 7.4 Hz, 1 H), 6.73 (d, J = 8.6 Hz,
1 H), 6.66 (dd, J = 8.6, 2.9 Hz, 1 H), 6.52 (d, J = 2.9 Hz, 1 H), 6.43 (d, J = 8.0 Hz, 1 H), 5.89 (br. s, 1 H), 5.62 (s, 1 H),
3.87 (s, 3 H), 3.27 (t, J = 8.3 Hz, 2 H), 3.13–3.01 (m, 2 H). 13C NMR (126 MHz, CDCl3) δ 167.2, 151.7, 149.6, 148.3,
144.6, 135.7, 130.2, 129.5, 128.5, 128.5, 126.1, 121.8, 117.7, 117.5, 116.2, 115.7, 113.4, 108.4, 63.9, 52.5, 51.9, 27.9.
Elemental analysis: Calcd for C24H20N2O4•1.05H2O: C, 68.74; H, 5.61; N, 6.68. Found: C, 68.42; H, 4.87; N, 6.60.
HRMS (ESI/TOF): m/z calcd for C24H20N2O4Cl− [M + Cl]−, 435.1117; found 435.1079 (Fig. S4 and S5 of SI).
Cell culture.

PC-3 and DU-145 cells were maintained in Minuteimal Essential Medium Eagle (MEM;
Sigma-Aldrich, St. Loius, MO, USA). HEK 293 and MEF cells were maintained in Dulbecco’s modified eagle’s
medium. Mediums were supplemented with 10% fetal bovine serum (FBS; Biowest, France) and 1% penicillin/
streptomycin (Sigma-Aldrich). Cells were cultured at 37 °C in humidified atmosphere of 5% CO2. The media was
changed once every 2 days. The culture was passaged using trypsin-EDTA (Sigma-Aldrich). Newly synthesized
compounds 1 and 2 were diluted in dimethyl sulfoxide (DMSO, Sigma -Aldrich).

Cell viability measurement.

PC-3, DU-145, HEK 293 and MEF cells were seeded with 1 × 104 cells/well
in 96-well plates. At 70–80% confluence, cells were exposed to compound 1, 2, DMSO, and MRS2365 for 48 h.
MTT and cytotoxicity assay (Bosterbio, CA, USA) was done to check the cell viability, as instructed by the manufacturer and the absorbance was measured at 570 nm using Magellan microplate reader (Tecan Group Ltd.,
Switzerland). Briefly, the cytotoxicity index was determinuteed using the untreated cells as control. DMSO was
used as the vehicle control against compound 1 and 2. The inhibition percentage of each compound, was calculated using the equation given below55.

™

% inhibition =

Ac − Atr
× 100
Ac

Ac, cell number of untreated cells; At, cell number of treated cells. A half maximal inhibitory concentration (IC50)
was determinuteed using the curve fitting program Prism 7.0 (GraphPad Software Inc., La Jolla, CA, USA).
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Cell proliferation assay. 96-well plates was seeded with 1 × 104 cells/well concentration of PC-3 and
DU-145. The overnight cultured cells were treated with compound 1 and 2 with the IC50 concentration or 2 mM
sodium orthovanadate (Na3VO4; positive control)56, and maintained in the 5% CO2 incubator for 24 h, 48 h, and
72 h. MTT cell proliferation and cytotoxicity assay was performed to measure the cell survival following the manufacturer’s instruction and the absorbance was measured at 570 nm using MagellanTM microplate reader. The cell
viability was calculated as the percentage of cell number of treated cells relative to cell number of untreated cells
at 24 h, 48 h, and 72 h.
Calcium kinetic assay. To carry out calcium kinetic assay, PC-3 and DU-145 cells 96-well black plate was
plated with 1 × 104 cells/well as previously described57. After overnight incubation, the cells were washed with
warm 1X phosphate buffered saline (PBS) (pH 7.2). The cells were further incubated with 2 µM Fura 2-AM
(Sigma-Aldrich) and 0.01% Pluronic F-127 (Sigma-Aldrich) in PBS for 30 minute at RT in dark condition.
Compound 1 and 2 were prepared in PBS with varying concentration of 6.25 µM, 12.5 µM, 25 µM, 50 µM, and
100 µM. The reaction was started on adding the compounds to the dye and the fluorescence intensity was measured using MagelanTM microplate reader at 37 °C at every 5 minute. The excitation was calculated in two different
alternative wavelength 340 nm and 380 nm and the emission of fluorescence was measured at 510 nm. The fold
change of intracellular calcium was calculated following the equation below58.

®

F340/380 =

tr
bg
F340
− F340

tr
bg
− F380
F380

tr
F340/380, fold change of intracellular calcium; F340
Emitted fluorescence intensities of samples with compound at
tr
bg
Background
340/510 nm; F380 Emitted fluorescence intensities of samples with compound at 380/510 nm; F340
bg
Background corcorrected emitted fluorescence intensities of samples without compound at 340/510 nm; F380
rected emitted fluorescence intensities of samples without compound at 380/510 nm. siRNA assay was also performed to check the specificity of the ligand binding with P2Y1R. Predesigned siRNA against human P2Y1R was
commercially synthesized (cat no. AM16708; Thermo Fisher Scientific, Waltham, MA, USA). PCa cells with the
confluence of 60–70% were transfected with 20 nM of siRNA by Lipofectamine RNAiMAX Transfection Reagents
(cat no. 13778030; Thermo Fisher Scientific). After 48 h of transfection, cells were measured to quantify the
changes in the intracellular calcium level.

Detection of reactive oxygen species (ROS) formation.

12-well plates was seeded with 1 × 105 cells/
well of PC-3 and DU-145 cells. After incubation overnight, the cells were treated with compound 1 and 2 for 5 h
with their respective IC50 concentration or 10 mM hydrogen peroxide (H2O2), as positive control for ROS59,60. The
cells were centrifuged at 3,000 rpm for 10 minute and the cell pellets were harvested. Cells were stained with 2 µM
molecular probe 2’,7’-dichlorodihydroflurescein diacetate (H2DCFDA) for 10 minute in the dark. Subsequently,
the stained cells were washed with warm PBS and incubated in the medium for 20 minute. Florescence of ROS
was measured at 485 nm and 538 nm using MagelanTM microplate reader. The fold change of ROS product was
determinuteed using the equation mentioned below61.
Fold increase =

Ftest − Fblank
Fcontrol − Fblank

Ftest - fluorescence of the treated wells; Fcontrol - fluorescence of the untreated wells; Fblank- fluorescence of the
unstained wells.

Apoptosis detection. To determinutee the ability of the compounds to induce cellular apoptosis, PC-3 and
DU-145 cells were plated with 5 × 105 cells/well in 6 well plate. Cells were treated with compound 1 or 2 at IC50
concentration of each compound for 48 h. The cells were washed twice with PBS, and resuspended in 50 µl binding buffer, 2.5 ml Annexin V-FITC and 0.5 µl 7-aminuteoactinomycin D (7-AAD, labels GC-rich regions of DNA
in permeabilized cells). The above mix of cells were incubated for 15 minute in the dark, followed by the addition
of 200 µl binding buffer. Approximately 300 cells were analyzed by epifluorescence microscope (Nikon-Eclipse
Ti-E inverted fluorescence microscope) under 20X objective for each analysis. Three biological repeats and two
technical were used for each condition.
Caspase 3/7 assay. PC-3 and DU-145 cells were plated in 96-well white plate at a density of 1 × 104 cells/
well 100 µl of cell culture medium. After 24 h of incubation, the cells were treated with IC50 concentration of the
compound 1 and 2 for 5 h. Caspase 3/7 activity of cells was measured using Caspase-Glo 3/7 Assay kit (Promega,
Madison USA). Cells were equilibrated at room temperature (RT) for 30 minute. 100 µl of Caspase-Glo reagent
was added to cells and incubated for 1 h at RT in dark condition. Luminuteescence of the sample was measured
using MagellanTM microplate reader. The fold increase of caspase 3/7 activity was calculated by applying the equation used for ROS.

®

Statistical analysis. All the experiments were performed with three biological and technical repeats. The
data was presented as the mean ± SEM. Statistical analysis was carried out by Student’s t-test using GraphPad
Prism 7.0 software. The differences among the experimental samples were analysed with one-way ANOVA.
Statistical significance was considered with the P-value of <0.05.
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